Global 3D Printed Drugs Market Report 2022: Disadvantages of Traditional Pharma Operations Fueling Growth –

DUBLIN–()–The “Global 3D Printed Drugs Market Research and Forecast 2022-2028” report has been added to from offer.

The global 3D printed drugs market is expected to grow at a CAGR of 9.1% during the forecast period. 3D printing as a technique is now well established and commonly used in industries such as automotive, healthcare (especially dental and orthopedic), and retail. 3D printed drugs are used to fuel innovation and progress in pharmaceutical industries.

3D printed drugs can be useful for orphan drugs and/or personalized drugs because these drugs are produced in small quantities. However, the first drug approved by the FDA was developed on a commercial scale in August 2015. Spritam (levetiracetam), the first 3D printed drug, was launched by Aprecia Pharmaceuticals. It uses a specially designed platform to make high-dose, fast-dissolving, chew-safe medications.

The market for 3D printed drugs is driven by the drawbacks of operations of traditional pharmaceutical units across the world. For example, traditional manufacturing unit operations such as milling, grinding, granulation and compression can result in a wide range of end product qualities in terms of drug loading, drug release, drug stabilization and stability of the pharmaceutical dosage form. 3D printed drugs are developed in such a way as not to alter the qualities of the final product.

Additionally, the high prevalence of chronic diseases such as arthritis, asthma, cancer, and diabetes, and the integration of 3D printing with conventional pharmaceutical technologies are major factors driving the growth of the market. Other factors contributing to the growth of the market include technological advancements in the healthcare industry owing to the growing demand for drugs coupled with the government’s emphasis and the geriatric population is in high demand for dissolvable tablets snapshots. For example, according to the United Nations, there were approximately 703 million people aged 65 or over in the world in 2019 and the number of older people is expected to double to 1.5 billion in 2050.

However, the market for 3D printed drugs is expected to be hampered by factors such as the antagonistic effects associated with the use of these products, the lack of federal controls related to these drugs, and the use of 3D printing to manufacture illicit drugs. Several industry players in emerging economies are expected to introduce 3D printed medicines along with increased healthcare spending in emerging economies to create opportunities in the market over the forecast period.

Sector outlook

The global 3D printed drugs market is segmented on the basis of dosage form, technology, and region. Based on dosage form, the market is segmented into tablet, capsules, multi-drug implant, nanoparticles, solutions, polymer encapsulated nanosuspension, and implant. Among the dosage forms, the tablet market is expected to grow at a significant CAGR during the forecast period. Further, based on technology, the market is categorized into inkjet printing, zipper dose, fusion deposition modeling (FDM) and stereolithography (SLA), etc. Apart from this, based on application, the market is categorized into dental, hearing and audibility prosthetics, medical implants, neurology and orthopedics. In 2019, the segment of 3D printed drugs for neurology held a major market share.

ALS Segment Expected to Hold Major Share of Global 3D Printed Drugs Market

Among the technologies, the SLA segment is expected to hold the major share in 2020 and is also expected to grow significantly over the forecast period. SLA is being used to make a 3D-printed multi-layered oral dosage form comprising four antihypertensive drugs, including irbesartan, atenolol, hydrochlorothiazide and amlodipine. Photopolymers are used in SLA to solidify resins or liquid materials. Drugs can be inserted into the polymer network to create pills containing active ingredients or to construct sustained release medical devices using this technology. This technology is the most effective for combining multiple drugs in a single 3D vial. Factors driving SLA technology in the 3D printing of the drug market include its ability to produce high-precision, isotropic and leak-proof prototypes, and the advanced material used in the SLA technique to end up with a smooth surface.

Main topics covered:

1. Summary of the report

2. Overview and Market Overview

3. Competitive Landscape

4. Market drivers

5. Market segmentation

6. Regional analysis

7. Company Profiles

Companies cited

  • 3D Systems Corp.

  • Anatomical Pty Ltd

  • Aprecia Pharmaceuticals, LLC

  • Cycle Pharmaceuticals Ltd.

  • FabRx Ltd.

  • Astra Zeneca Plc

  • Biomedical Modeling Inc.,


  • EnvisionTEC GmbH

  • GlaxoSmithKline Plc

  • Linx Printing Technologies

  • Materialize NV

  • Merck KGaA

  • Organovo Holdings, Inc.

  • Pharma Excipients International SA

  • PreScouter, Inc.

  • Prodways Group SA

  • Renishaw APIs

  • Siemens AG

  • SLM Solutions Group SA

For more information on this report, visit